HF Advisory Group LLC Purchases 7,803 Shares of Sanofi (NASDAQ:SNY)

HF Advisory Group LLC raised its stake in Sanofi (NASDAQ:SNY) by 62.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 20,369 shares of the company’s stock after buying an additional 7,803 shares during the period. HF Advisory Group LLC’s holdings in Sanofi were worth $1,013,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Cardinal Capital Management lifted its position in shares of Sanofi by 0.3% in the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after purchasing an additional 201 shares during the period. Daiwa Securities Group Inc. lifted its position in shares of Sanofi by 3.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after purchasing an additional 216 shares during the period. Sage Rhino Capital LLC lifted its position in shares of Sanofi by 2.8% in the 3rd quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock worth $468,000 after purchasing an additional 240 shares during the period. Gallacher Capital Management LLC lifted its position in shares of Sanofi by 4.5% in the 3rd quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock worth $307,000 after purchasing an additional 245 shares during the period. Finally, Captrust Financial Advisors lifted its position in shares of Sanofi by 0.9% in the 3rd quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock worth $996,000 after purchasing an additional 246 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

NASDAQ SNY traded down $0.48 during mid-day trading on Thursday, reaching $45.63. 744,330 shares of the stock were exchanged, compared to its average volume of 1,843,888. The business’s 50 day moving average is $47.55 and its 200-day moving average is $48.69. Sanofi has a 1 year low of $42.63 and a 1 year high of $57.82. The company has a market capitalization of $115.43 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.71 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. On average, equities research analysts forecast that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is currently 58.47%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SNY. Morgan Stanley started coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.